CLINICAL TRIALS PROFILE FOR DESONIDE

All Clinical Trials for desonide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00608777 ↗	Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)	Terminated	Genentech, Inc.	Phase 4	2008-01-01	The purpose of this study is to determine if calcipotriene/bethamethasone can safely and effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving efalizumab (Raptiva) for moderate to severe plaque psoriasis. It is hypothesized that calcipotriene/betamethasone (Taclonex) could be used to manage LMB and thus allow patients to continue efalizumab without interruption.
NCT00608777 ↗	Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)	Terminated	Derm Research, PLLC	Phase 4	2008-01-01	The purpose of this study is to determine if calcipotriene/bethamethasone can safely and effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving efalizumab (Raptiva) for moderate to severe plaque psoriasis. It is hypothesized that calcipotriene/betamethasone (Taclonex) could be used to manage LMB and thus allow patients to continue efalizumab without interruption.
NCT00690833 ↗	Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis	Completed	Wake Forest University	Phase 4	2007-08-01	The purpose of this research study is to better understand how this study drug works when people use it to treat atopic dermatitis. Desonate has been approved by the US Food and Drug Administration (FDA) for atopic dermatitis.
NCT00828412 ↗	Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis	Completed	Promius Pharma, LLC	Phase 4	2009-03-01	This study compares the effectiveness of two topical creams for atopic dermatitis in pediatric subjects. Subjects will be randomly assigned to use one of the two creams twice daily for 6 weeks or until clear.
NCT01542138 ↗	Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation	Completed	Hospital Central "Dr. Ignacio Morones Prieto"	Phase 4	2011-07-01	Axillary hyperpigmentation is a frequent consultation in dark skin populations although its exact prevalency is unknown. Currently, there are not studies about physiopathology and treatment for this entity. The objective is to evaluate the depigmenting effect of topical 4% niacinamide versus 0.05% desonide in axillary hyperpigmentation. At least 30 axillas with hyperpigmentation in individuals of phototype III-V, aged 18-50 years are going to be randomly assigned to receive niacinamide, desonide or placebo daily. No hygienic habits will not be modified. Volunteers will be evaluated at baseline and for 9 weeks, by means of histological, histochemical and immunohistochemistry analysis, as well as Transepidermal Water Loss (TEWL), colorimetry, clinically and by photography control.
NCT01542138 ↗	Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation	Completed	Universidad Autonoma de San Luis Potosí	Phase 4	2011-07-01	Axillary hyperpigmentation is a frequent consultation in dark skin populations although its exact prevalency is unknown. Currently, there are not studies about physiopathology and treatment for this entity. The objective is to evaluate the depigmenting effect of topical 4% niacinamide versus 0.05% desonide in axillary hyperpigmentation. At least 30 axillas with hyperpigmentation in individuals of phototype III-V, aged 18-50 years are going to be randomly assigned to receive niacinamide, desonide or placebo daily. No hygienic habits will not be modified. Volunteers will be evaluated at baseline and for 9 weeks, by means of histological, histochemical and immunohistochemistry analysis, as well as Transepidermal Water Loss (TEWL), colorimetry, clinically and by photography control.

Clinical Trial Conditions for desonide

Condition Name

Condition Name for desonide
Intervention	Trials
Atopic Dermatitis	3
Plaque Psoriasis	2
Dermatitis, Atopic	1
Eczema	1

Condition MeSH

Condition MeSH for desonide
Intervention	Trials
Dermatitis, Atopic	5
Eczema	4
Dermatitis	4
Psoriasis	3

Clinical Trial Locations for desonide

Trials by Country

Trials by Country for desonide
Location	Trials
United States	11
Poland	1
Mexico	1

Trials by US State

Trials by US State for desonide
Location	Trials
North Carolina	3
California	1
Tennessee	1
Massachusetts	1
Texas	1

Clinical Trial Progress for desonide

Clinical Trial Phase

Clinical Trial Phase for desonide
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	5
Phase 3	2

Clinical Trial Status

Clinical Trial Status for desonide
Clinical Trial Phase	Trials
Completed	4
NOT_YET_RECRUITING	2
Unknown status	2

Clinical Trial Sponsors for desonide

Sponsor Name

Sponsor Name for desonide
Sponsor	Trials
Wake Forest University	1
URGO Recherche, Innovation et Dveloppement	1
Promius Pharma, LLC	1

Sponsor Type

Sponsor Type for desonide
Sponsor	Trials
Industry	8
Other	6
UNKNOWN	1

Desonide (Topical Corticosteroid): Clinical Trials Update, Market Analysis, and Projection

Last updated: April 26, 2026

What is desonide and how is it positioned commercially?

Desonide is a low-to-mid potency topical corticosteroid used for inflammatory dermatoses, typically eczema/dermatitis subtypes. In product commercial terms, desonide is a mature molecule with patent-expired status across most major markets, which drives a high share of generic and authorized-label variants rather than innovation-led market expansion.

What is the current clinical-trials landscape for desonide?

No complete, audit-ready “live pipeline” summary can be produced from the information provided. A correct clinical trials update requires molecule-level trial identification (NCT or equivalent registry IDs), recruitment status, endpoints, phase, and geography, which are not included in the prompt.

How large is the addressable market for topical corticosteroids that includes desonide use?

Because desonide’s market is not segmented as a standalone line item in most public market research databases, the most decision-relevant view is the topical corticosteroid category (and adjacent dermatoses self-care) rather than a molecule-only TAM.

Key category dynamics that determine where desonide sits:

• Mature market with generic pressure: Low-potency topical steroids face strong price compression from generics and authorized formulations.
• Prescriber trust and formulary inertia: Low-to-mid potency agents are adopted through established clinical practice and insurance formularies, not through new mechanism claims.
• Competitive set is class-based: Competition comes from alternative corticosteroids and fixed-combination products (where permitted by labeling), not from novel delivery for desonide specifically.
• Distribution advantage matters: Brand-to-generic switching depends on pharmacy reimbursement and payer contracting rather than efficacy differentiation.

Where does desonide compete most directly?

Desonide competes within the low-to-mid potency topical steroid segment against:

• Other topical corticosteroids with overlapping labeled indications (eczema/dermatitis variants).
• Lower-cost generics with equivalent or broader formulation availability (cream/ointment/gel/foam depending on country).
• Formulary-preferred agents that may have better tier placement.

Because desonide is not a differentiated innovation platform, its commercial outcome is driven primarily by pricing, channel availability, and label fit rather than clinical-trial novelty.

What pricing and market-access factors will shape desonide revenue?

For mature, largely generic topical dermatology products, revenue is typically governed by:

• Net price erosion: Competition from multi-source generics and pharmacy benefit contracting.
• Formulation mix: Ointment vs cream vs lotion can shift demand within dermatology categories, depending on payer coverage and patient preference.
• Channel mix: Retail vs mail order vs institutional dermatology clinics can change throughput and contracted pricing.
• Seasonality and cyclic dermatology visits: Demand tracks flare patterns and seasonal eczema trends, but the effect is usually modest relative to price compression.

Market projection logic (what drives growth or decline)?

Without molecule-specific trial signals or molecule-specific published unit data, a credible projection can only be stated at the mechanism-and-class level. The drivers for topical corticosteroids broadly apply:

• Volume: Stable underlying incidence of eczema/dermatitis; volume growth is limited by generic penetration and steady prescribing patterns.
• Price: Typically declines over time in multi-source markets.
• Mix: Growth can occur when formulations with higher patient adherence (vehicle acceptability) gain share, but desonide’s class position is less likely to produce step-change growth.

A practical investment or R&D planning view is:

• Upside ceiling: constrained by generic availability and substitution.
• Downside risk: continued price erosion and payer contracting against low-potency steroids.
• Most reliable path to growth: incremental formulation strategy, improved tolerability/adherence under existing labeling (not new mechanism).

What clinical evidence would matter most for future desonide differentiation?

For a mature topical steroid, the decision-grade clinical data (if pursued) would be:

• Vehicle efficacy and patient acceptability: time to symptom improvement, adherence proxies, and tolerability (skin atrophy, irritation).
• Safety in special populations: children, long-term intermittent dosing, and sensitive skin areas.
• Comparative effectiveness against formulary competitors: head-to-head designs where possible to support formulary changes.

No registry-backed trial update can be stated from the prompt.

Bottom-line market view for desonide

• Desonide is best treated as a defensible niche within low-to-mid potency topical corticosteroids, where performance is determined by contracting, price, and product availability.
• Without new clinical differentiation and given mature generic competition, revenue growth is typically modest and comes from share stability or formulation-specific uptake rather than breakthrough expansion.

Key Takeaways

• Desonide is a mature topical corticosteroid where commercial performance is driven more by pricing and formulary access than by innovation.
• A complete clinical trials update is not supportable from the provided inputs because it requires registry-specific trial identification and statuses.
• Market growth for desonide is constrained by generic substitution; realistic upside comes from formulation mix and payer/channel strategy rather than new mechanism claims.

FAQs

1. Is desonide protected by active patents in major markets?
   The prompt does not provide patent status details, and a molecule-specific protection map cannot be produced without explicit jurisdiction and patent identifiers.

2. Are there new phase 3 trials for desonide?
   A trial phase-by-phase update cannot be produced because no registry trial identifiers or recruitment statuses are included.

3. What conditions is desonide primarily used for?
   Desonide is used for inflammatory dermatoses such as eczema/dermatitis types, based on typical labeled use for low-to-mid potency topical corticosteroids; the prompt does not include exact label lines for each jurisdiction.

4. How does desonide typically compete in formularies?
   It competes within low-to-mid potency topical steroid classes where payer tier placement and contracted net price determine share as much as efficacy.

5. What are the most likely paths to commercial growth?
   The most likely levers are product availability (formulation/vehicle mix), payer contracting, and adherence-oriented formulation improvements under existing therapeutic positioning.

---

References

[1] No sources were provided in the prompt.